



**TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION  
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)**

Madrid, 31 July 2024

In compliance with the information duties provided for in article 227 of the Law 6/2023, of 17 March, on the Securities Markets and Investment Services, Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, "**ROVI**" or the "**Company**") hereby discloses to the Spanish National Securities Market Commission the following

**OTHER RELEVANT INFORMATION**

**Modification of securities and cash balances associated with the Liquidity Contract**

In relation to the current liquidity contract entered into with Bestinver SV, S.A. (the "**Liquidity Contract**") and in compliance with the provisions of Circular 1/2017, of April 26, 2017, of the National Securities Market Commission, on liquidity contracts, as amended by Circular 2/2019, of November 27, it is hereby notified that ROVI and Bestinver SV, S.A. have agreed to modify the securities and cash balances associated with the Liquidity Contract which shall hereinafter be as follows:

- Securities account balance after modification: 6,000 shares.
- Cash account balance after modification: 570,000.00 euros.

Mr. Juan López-Belmonte Encina

Chairman of the Board of Directors and  
Chief Executive Officer (*Consejero Delegado*)  
Laboratorios Farmacéuticos ROVI, S.A.